| Accession | SAMC1714153 | ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accession in Other Database | GSA-Human: HRS192098 | ||||||||||||||||||||||||||||||||||||||||||
| Sample name | Z15 0.5 uM treated LNCaP cell_3 | ||||||||||||||||||||||||||||||||||||||||||
| Title | Z15_0.5_3 | ||||||||||||||||||||||||||||||||||||||||||
| Sample type | Human sample | ||||||||||||||||||||||||||||||||||||||||||
| Organism | Homo sapiens | ||||||||||||||||||||||||||||||||||||||||||
| Description | LNCaP cells were only treated with indicated compounds, without any other treatment | ||||||||||||||||||||||||||||||||||||||||||
| Attributes |
|
||||||||||||||||||||||||||||||||||||||||||
| Custom attributes |
|
||||||||||||||||||||||||||||||||||||||||||
| Release date | 2021-06-10 | ||||||||||||||||||||||||||||||||||||||||||
| BioProject Accession | PRJCA005389 | ||||||||||||||||||||||||||||||||||||||||||
| Submitter | Jinmign Zhou (zhou_jim@hotmail.com) | ||||||||||||||||||||||||||||||||||||||||||
| Organization | Zhejiang normal university | ||||||||||||||||||||||||||||||||||||||||||
| Submission date | 2023-06-18 |
| Resource name | Description |
|---|---|
| GSA-Human (1) | - |
| HRA000921 (Open Access) | Clinical resistance such as androgen receptor (AR) mutation, AR overexpression and AR splice variants restrict the second-generation antiandrogens benefit in castration-resistant prostate cancer (CRPC) patients. Several strategies have been involved in the development of novel antiandrogens to circumvent the occurring resistance. In this work, based on rational drug design, we discovered and identified a bifunctional small molecule Z15 as a potent AR antagonist and the AR selective degrader. Here, in this bioproject, we performed a RNA-seq to analysis the influence of Z15 on prostate cancer cells. |